Manuel Merlos

Manuel Merlos

Auto-generated profile, based on publicly available information

Manuel Merlos

Drug Development and Clinical Research, Palau Pharma, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TCTeresa Coll
Teresa Coll
EEElena Eyre
Elena Eyre
RRRicardo Rodríguez-Calvo
Ricardo Rodríguez-Calvo
XPXavier Palomer
Xavier Palomer
RSRosa M. Sánchez
Rosa M. Sánchez
Manuel Vazquez-CarreraManuel Vazquez-Carrera
Manuel Vazquez-Carrera
Here we report that in skeletal muscle cells the contribution to insulin resistance and inflammation of two common dietary long-chain fatty acids depends on the channeling of these lipids to distinct cellular metabolic fates. Exposure of cells to the saturated fatty acid palmitate led to enhanced diacylglycerol levels and the consequent activation of the protein kinase Cθ/nuclear factor κB pathway, finally resulting in enhanced interleukin 6 secretion and down-regulation of the expression of genes involved in the control of the oxidative capacity of skeletal muscle (peroxisome proliferator-activated receptor (PPAR)γ-coactivator 1α) and triglyceride synthesis (acyl-coenzyme A: diacylglycerol acyltransferase 2). In contrast, exposure to the monounsaturated fatty acid oleate did not lead to these changes. Interestingly, co-incubation of cells with palmitate and oleate reversed both inflammation and impairment of insulin signaling by channeling palmitate into triglycerides and by up-regulating the expression of genes involved in mitochondrial β-oxidation, thus reducing its incorporation into diacylglycerol. Our findings support a model of cellular lipid metabolism in which oleate protects against palmitate-induced inflammation and insulin resistance in skeletal muscle cells by promoting triglyceride accumulation and mitochondrial β-oxidation through PPARα- and protein kinase A-dependent mechanisms.

29 April 1998 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJavier Bartroli
Javier Bartroli
ETEnric Turmo
Enric Turmo
MAMònica Algueró
Mònica Algueró
EBEulàlia Boncompte
Eulàlia Boncompte
MVMaria L. Vericat
Maria L. Vericat
JFJavier Forn
Javier Forn

9 March 2012 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
LRL Romero
L Romero
DZD Zamanillo
D Zamanillo
XNX Nadal
X Nadal
RSR Sánchez‐Arroyos
R Sánchez‐Arroyos
IRI Rivera‐Arconada
I Rivera‐Arconada
JVJm Vela
Jm Vela
BACKGROUND AND PURPOSEThe sigma‐1 (σ1) receptor is a ligand‐regulated molecular chaperone that has been involved in pain, but there is limited understanding of the actions associated with its pharmacological modulation. Indeed, the selectivity and pharmacological properties of σ1receptor ligands used as pharmacological tools are unclear and the demonstration that σ1receptor antagonists have efficacy in reversing central sensitization‐related pain sensitivity is still missing.EXPERIMENTAL APPROACHThe pharmacological properties of a novel σ1receptor antagonist (S1RA) were first characterized. S1RA was then used to investigate the effect of pharmacological antagonism of σ1receptors onin vivonociception in sensitizing conditions and onin vitrospinal cord sensitization in mice. Drug levels and autoradiographic,ex vivobinding for σ1receptor occupancy were measured to substantiate behavioural data.KEY RESULTSFormalin‐induced nociception (both phases), capsaicin‐induced mechanical hypersensitivity and sciatic nerve injury‐induced mechanical and thermal hypersensitivity were dose‐dependently inhibited by systemic administration of S1RA. Occupancy of σ1receptors in the CNS was significantly correlated with the antinociceptive effects. No pharmacodynamic tolerance to the antiallodynic and antihyperalgesic effect developed following repeated administration of S1RA to nerve‐injured mice. As a mechanistic correlate, electrophysiological recordings demonstrated that pharmacological antagonism of σ1receptors attenuated the wind‐up responses in spinal cords sensitized by repetitive nociceptive stimulation.CONCLUSIONS AND IMPLICATIONSThese findings contribute to evidence identifying the σ1receptor as a modulator of activity‐induced spinal sensitization and pain hypersensitivity, and suggest σ1receptor antagonists as potential novel treatments for neuropathic pain.

4 January 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CACarmen Almansa
Carmen Almansa
AAAlberto F. de Arriba
Alberto F. de Arriba
FCFernando L. Cavalcanti
Fernando L. Cavalcanti
LGLuis A. Gómez
Luis A. Gómez
AMAgustí Miralles
Agustí Miralles
JFJavier Forn
Javier Forn

1 January 2006 in Endocrinology
Verified
Journal Article
Closed access
MJMireia Jové
Mireia Jové
APAnna Planavila
Anna Planavila
RSRosa M. Sánchez
Rosa M. Sánchez
MMManuel Merlos
Manuel Merlos
Juan LagunaJuan Laguna
Juan Laguna
Manuel Vazquez-CarreraManuel Vazquez-Carrera
Manuel Vazquez-Carrera
The mechanisms responsible for increased expression of TNF-α in skeletal muscle cells in diabetic states are not well understood. We examined the effects of the saturated acid palmitate on TNF-α expression. Exposure of C2C12 skeletal muscle cells to 0.75 mm palmitate enhanced mRNA (25-fold induction, P < 0.001) and protein (2.5-fold induction) expression of the proinflammatory cytokine TNF-α. This induction was inversely correlated with a fall in GLUT4 mRNA levels (57% reduction, P < 0.001) and glucose uptake (34% reduction, P < 0.001). PD98059 and U0126, inhibitors of the ERK-MAPK cascade, partially prevented the palmitate-induced TNF-α expression. Palmitate increased nuclear factor (NF)-κB activation and incubation of the cells with the NF-κB inhibitors pyrrolidine dithiocarbamate and parthenolide partially prevented TNF-α expression. Incubation of palmitate-treated cells with calphostin C, a strong and specific inhibitor of protein kinase C (PKC), abolished palmitate-induced TNF-α expression, and restored GLUT4 mRNA levels. Palmitate treatment enhanced the expression of phospho-PKCθ, suggesting that this PKC isoform was involved in the changes reported, and coincubation of palmitate-treated cells with the PKC inhibitor chelerythrine prevented the palmitate-induced reduction in the expression of IκBα and insulin-stimulated Akt activation. These findings suggest that enhanced TNF-α expression and GLUT4 down-regulation caused by palmitate are mediated through the PKC activation, confirming that this enzyme may be a target for either the prevention or the treatment of fatty acid-induced insulin resistance.

1 October 2006 in Diabetes
Verified
Journal Article
Open access
PDF file
TCTeresa Coll
Teresa Coll
MJMireia Jové
Mireia Jové
RRRicardo Rodríguez-Calvo
Ricardo Rodríguez-Calvo
EEElena Eyre
Elena Eyre
XPXavier Palomer
Xavier Palomer
Manuel Vazquez-CarreraManuel Vazquez-Carrera
Manuel Vazquez-Carrera
The mechanisms by which elevated levels of free fatty acids cause insulin resistance are not well understood. Previous studies have reported that insulin-resistant states are characterized by a reduction in the expression of peroxisome proliferator–activated receptor-γ coactivator (PGC)-1, a transcriptional activator that promotes oxidative capacity in skeletal muscle cells. However, little is known about the factors responsible for reduced PGC-1 expression. The expression of PGC-1 mRNA levels was assessed in C2C12 skeletal muscle cells exposed to palmitate either in the presence or in the absence of several inhibitors to study the biochemical pathways involved. We report that exposure of C2C12 skeletal muscle cells to 0.75 mmol/l palmitate, but not oleate, reduced PGC-1α mRNA levels (66%; P < 0.001), whereas PGC-1β expression was not affected. Palmitate led to mitogen-activated protein kinase (MAPK)–extracellular signal–related kinase (ERK) 1/2 (MEK1/2) activation. In addition, pharmacological inhibition of this pathway by coincubation of the palmitate-exposed cells with the MEK1/2 inhibitors PD98059 and U0126 prevented the downregulation of PGC-1α. Furthermore, nuclear factor-κB (NF-κB) activation was also involved in palmitate-mediated PGC-1α downregulation, since the NF-κB inhibitor parthenolide prevented a decrease in PGC-1α expression. These findings indicate that palmitate reduces PGC-1α expression in skeletal muscle cells through a mechanism involving MAPK-ERK and NF-κB activation.